Aurinia Pharmaceuticals Inc. Stock price Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 223M 302M | Sales 2025 * | 288M 389M | Capitalization | 723M 979M |
---|---|---|---|---|---|
Net income 2024 * | -6M -8.12M | Net income 2025 * | 58M 78.54M | EV / Sales 2024 * | 1.7 x |
Net cash position 2024 * | 344M 466M | Net cash position 2025 * | 390M 529M | EV / Sales 2025 * | 1.16 x |
P/E ratio 2024 * |
-90.9
x | P/E ratio 2025 * |
12.7
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.55% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
1st Jan change | Capi. | |
---|---|---|
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |